|Bid||123.99 x 1100|
|Ask||123.97 x 1100|
|Day's Range||122.51 - 124.80|
|52 Week Range||86.16 - 128.54|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||38.69|
|Earnings Date||Jul 14, 2021 - Jul 19, 2021|
|Forward Dividend & Yield||1.80 (1.47%)|
|Ex-Dividend Date||Apr 14, 2021|
|1y Target Est||135.63|
Quest Diagnostics Inc on Thursday reported a first-quarter profit that exceeded Wall Street expectations as a recovery in its non-COVID-19 businesses offset a slowdown in coronavirus testing. Quest, Abbott Laboratories, and others in the sector have benefited from surging demand for COVID-19 testing, bringing in billions in sales last year. "We continue to expect the decline in clinical demand for COVID-19 molecular testing in the second half of 2021 versus our expectations for the first half," Mark Guinan, Quest's chief financial officer, said during an investor call to discuss the quarterly results.
In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss which stocks could be the biggest losers from this trend. Keith Speights: Now I came across another story recently, and in some ways it's surprising. While increasingly more Americans are receiving COVID-19 vaccines, the rates of COVID testing are falling pretty significantly in the United States.
Abbott Laboratories (NYSE: ABT) disappointed some investors after first-quarter revenue lagged behind analysts' estimates. Investors probably were hoping that Abbott's coronavirus diagnostics along with the strength of its star product -- the FreeStyle Libre continuous glucose monitoring system -- would offer revenue a bigger push. Abbott's revenue still rose more than 35% to $10.5 billion in the first quarter.